Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist


ÖZÇELİK B., Turkyilmaz C., ÖZGÜN M. T., SERİN İ. S., Batukan C., Ozdamar S., ...Daha Fazla

FERTILITY AND STERILITY, cilt.93, sa.5, ss.1609-1614, 2010 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 93 Sayı: 5
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/j.fertnstert.2009.02.054
  • Dergi Adı: FERTILITY AND STERILITY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1609-1614
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Objective: To evaluate the protective effect of GnRH agonist for the prevention of ovarian reserve during treatment with paclitaxel and cisplatin. Design: Experimental study. Settings: University-based research laboratory. Animal(s): Seventy female Wistar-Albino rats. Intervention(s): Each group consisted of 10 rats. Group I served as controls. Groups without GnRH agonist (groups 2, 3, and 4) were administered paclitaxel and cisplatin, respectively; the remaining groups (groups 5, 6, and 7) were given the same regimens with GnRH agonist. The GnRH agonist (leuprolide acetate; 2.5 mu g/d subcutaneously for 5 weeks) was started four weeks before chemotherapy to achieve anovulation. Paclitaxel (7.5 mg/kg) and cisplatin (5 mg/kg) were administered intraperitoneally on the 28th day as a single dose. Main Outcome Measure(s): One week after the chemotherapy, the animals were euthanized and primordial, primary, secondary, and tertiary follicle counts were evaluated. Result(s): Primordial, primary, and tertiary follicle counts in group 5 (paclitaxel plus GnRH agonist) and tertiary follicles in groups 2 and 3 had not decreased, but there was a significant decrease in other treatment groups compared with controls (P < 0.05). Binary comparison between all groups demonstrated that the primordial follicle count in group 5 was comparable to those of the controls. Conclusion(s): Paclitaxel plus GnRH agonist treatment may be an appropriate option for patients deserving further fertility in the preservation of primordial follicles. (Fertil Steril (R) 2010;93:1609-14. (C)2010 by American Society for Reproductive Medicine.)